Iprindole

Iprindole is a tricyclic antidepressant (TCA) that was developed in the 1960s by the British pharmaceutical company Lederle Laboratories. It is used primarily in the treatment of depression and anxiety disorders, although it has also been used off-label for other conditions such as chronic pain and insomnia.

Pharmacology[edit | edit source]

Iprindole works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that are involved in mood regulation. This increases the amount of these neurotransmitters available in the brain, which can help to alleviate symptoms of depression and anxiety. Unlike many other TCAs, iprindole does not have significant anticholinergic effects, which means it is less likely to cause side effects such as dry mouth, constipation, and blurred vision.

Clinical use[edit | edit source]

Iprindole is typically used in cases where other antidepressants have not been effective or have caused unacceptable side effects. It is usually taken orally, with the dose adjusted according to the patient's response and tolerance. The most common side effects of iprindole include dizziness, drowsiness, and nausea. In rare cases, it can cause more serious side effects such as cardiac arrhythmias and seizures.

History[edit | edit source]

Iprindole was first synthesized in the 1960s by Lederle Laboratories, a British pharmaceutical company. It was one of a number of new TCAs developed during this period, as researchers sought to improve on the efficacy and safety profile of the first-generation antidepressants. Despite its promising early results, iprindole has not been widely adopted in clinical practice, possibly due to the availability of newer and more effective antidepressants.